News Search Results
Nov 04, 2024, 06:00 ET HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration
therapy for Alzheimer's. With an extensive intellectual property portfolio, HuidaGene is a leader in genome medicines for neurology and ophthalmology. Learn more at
More news about: HuidaGene Therapeutics
Nov 04, 2024, 05:15 ET Formosa Pharmaceuticals Announces Successful Top-Line Results from CPN-303, a Phase 3 Trial in Chinese Subjects for the Treatment of Inflammation and Pain after Cataract Surgery
Pharmaceuticals, Inc. Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®), through which APP13007 was developed, improves
More news about: Formosa Pharmaceuticals Inc.,
Nov 01, 2024, 07:00 ET HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update
endocrine, circulatory, and urologic diseases for over 50 years. HanAll has also expanded its focus to immunology, oncology, neurology, and ophthalmology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. One of its lead pipeline assets,
More news about: HanAll Biopharma
Oct 31, 2024, 09:36 ET Formosa Pharmaceuticals and DÁVI Farmacêutica Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
than 12 years. DÁVI is one of the key players in the Portuguese Market, with over 100 years' history in the distribution and promotion of branded ophthalmology products. Clobetasol propionate ophthalmic suspension, 0.05% (APP13007), approved by the U.S. Food and Drug Administration (FDA) in March, 2024,
More news about: Formosa Pharmaceuticals Inc.,
Oct 31, 2024, 07:30 ET Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
[4] Wilson, M. W. et al, "Intraocular MDMX Inhibition by ALRN-6924: A Targeted Strategy to Reactivate p53 in Retinoblastoma." Investigative Ophthalmology & Visual Science, 2023 June;64(8): 1272 About Aileron Therapeutics Aileron Therapeutics is a biopharmaceutical company
More news about: Aileron Therapeutics, Inc.; Advancium Health Network
Oct 30, 2024, 07:45 ET FDA Grants Orphan Drug Designation to Capsida Biotherapeutics for Potential Treatment of STXBP1 Developmental and Epileptic Encephalopathy
partnerships with AbbVie, Lilly, CRISPR Therapeutics, and the AbbVie partnership was expanded to include ophthalmology disorders. Capsida was founded in 2019 by lead investors Versant Ventures and Westlake Village BioPartners
More news about: Capsida Biotherapeutics
Oct 30, 2024, 07:00 ET InMode Reports Third Quarter 2024 Financial Results; Quarterly GAAP Revenue of $130.2 Million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024)
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com. Forward-Looking
More news about: InMode Ltd.
Oct 30, 2024, 06:50 ET Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Oct 29, 2024, 08:30 ET Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at the American College of Gastroenterology (ACG) Annual Meeting
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Oct 29, 2024, 08:00 ET Solutionreach Introduces Secure Documents Tool to Aid Optometry Practices with FTC Eyeglass Rule Compliance
commitment to providing best-in-class solutions for patient communication and practice management, Solutionreach is proud to offer optometry and ophthalmology practices a solution that supports both regulatory and patient-care needs. To learn more about Solutionreach and its new Secure Documents
More news about: Solutionreach
Oct 28, 2024, 21:13 ET GC Biopharma and Novelty Nobility Enter into Joint Research and Development Agreement for Geographic Atrophy Therapies
and develops bispecific antibodies and antibody-drug conjugates (ADCs). The company primarily focuses on oncology but also other areas such as ophthalmology and immunology where its scientific novelty can make a meaningful impact on patients' lives. This press release may contain biopharmaceuticals
More news about: GC Biopharma
Oct 28, 2024, 19:53 ET Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces the latest clinical results of a multicenter, open-label Phase 2 study (ClinicalTrials.gov, NCT05970978) of
More news about: Innovent Biologics
Oct 28, 2024, 07:03 ET Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY
approvals.The SMO business continued steady growth, maintaining significant advantages in multiple therapeutic areas (cardiovascular disease, ophthalmology, rheumatology, central nervous system, endocrinology, medical aesthetics and rare tumors, etc.).WuXi Biology:
More news about: WuXi AppTec
Oct 26, 2024, 13:00 ET Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at Kidney Week 2024
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Oct 25, 2024, 14:21 ET Sun Pharma Presents LEQSELVI™ (deuruxolitinib) Data Highlighting Clinical Efficacy & Durability for Treatment of Alopecia Areata at the 2024 Fall Clinical Dermatology Conference
generic company in the US as well as Global Emerging Markets. Sun's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharma
Oct 25, 2024, 08:30 ET Studies Show Sun Pharma's WINLEVI® (clascoterone) Cream 1% Reduces Sebum Levels and is Suitable for Combination With Other Commonly Used Topical Acne Medications
company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharma
Oct 25, 2024, 08:00 ET Covenant High Plains Surgery Center completes 100th Inspire® Therapy Procedure
well as advanced surgical treatment options in bariatrics, ENT, general surgery, GI, gynecology, interventional pain, neuro & spine surgery, ophthalmology, orthopedics, maxillofacial, plastic & reconstructive surgery, podiatry, and urology to patients from Texas
More news about: Covenant High Plains Surgery Center
Oct 25, 2024, 07:00 ET Sun Pharma Announces Multiple Data Presentations Highlighting its Dermatology Portfolio to be Featured at the 2024 Fall Clinical Dermatology Conference
generic company in the US as well as Global Emerging Markets. Sun's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharma
Oct 24, 2024, 07:03 ET InMode Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales of Morpheus8 Radiofrequency Devices and Cartridge Accessories
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit
More news about: InMode Ltd.
Oct 24, 2024, 06:45 ET Mallinckrodt to Report Earnings Results for Third Quarter 2024
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Oct 23, 2024, 14:08 ET Piramal Pharma Limited Announces Results for Q2 and H1 FY25
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd
Oct 23, 2024, 14:01 ET Piramal Pharma Limited Announces Results for Q2 and H1 FY25
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd
Oct 23, 2024, 08:00 ET Pyx Health Appoints New Chief Financial Officer
for one of the largest non-profit hospice providers in the nation. Most recently, Ehrhardt served as CFO at a private equity-backed, multistate ophthalmology practice in Denver, Colorado, where he successfully scaled financial operations. "With nearly 15 years of
More news about: Pyx Health
Oct 22, 2024, 08:36 ET Dialog Health and AMSURG Solidify Strategic Partnership to Revolutionize Patient Communication with Dialog Health's Advanced, Two-Way Texting Platform
health systems, the organization delivers high-quality patient care across a diverse spectrum of medical specialties, including gastroenterology, ophthalmology and orthopedics. With a focus on strategic growth and innovation, AMSURG is committed to transforming the future of ambulatory surgery center care
More news about: Dialog Health
Oct 21, 2024, 16:00 ET Nanoscope Publishes Breakthrough Showing MCO-010 Treatment Arrests Neurodegeneration
bipolar cells in the inner retina," said Dr. Vinit Mahajan, Professor and Vice Chair for Research, Department of Ophthalmology at Stanford University. "This disease-modifying aspect of MCO-010 has also been observed in an animal model of
More news about: Nanoscope Therapeutics